CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
Venlafaxine +1 moredrug
Likely dose
Venlafaxine 375 mg orally dailyAI-extracted
Key inclusion· 3
  • ✓Meets criteria for current marijuana addiction with marijuana as primary drug of abuse
  • ✓Meets criteria for major depression or dysthymic disorder with Hamilton Depression Inventory score ≥12
  • ✓Clinically depressed for at least 3 months during period of active marijuana use
Key exclusion· 9
  • ✕Meets criteria for past manic or psychotic disorder, unless substance-related
  • ✕History of seizure disorder
  • ✕Chronic organic mental syndrome
  • ✕Significant suicide risk based on current assessment and history of attempts

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00131456
NCT00131456Phase 2Completed
CompareCT.gov

Marijuana Addiction and Depression: Venlafaxine Treatment

New York State Psychiatric Institute·interventional·Posted Aug 18, 2005·Updated Apr 24, 2019

In Brief

A Phase 2 clinical trial evaluating Venlafaxine and Placebo for Depression and Marijuana Abuse. Completed, enrolled 123 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Marijuana Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 18, 2005
Enrollment StartMar 1, 2004
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.9 years ago

Interventions

Venlafaxinedrug

375mg/day

Placebodrug

Placebo